« Back
Home /
Bortezomib (PS-341)

Bortezomib (PS-341)

Item no.	M1686-200mg
Manufacturer	AbMole
CASRN	179324-69-7
Amount	200mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	0,9927
Citations	Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients. Koda, et al . Rinsho Ketsueki. 2012 Aug,53(8):760-4. PMID: 22975816 . BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Rushworth, et al . Cell Signal. 2012 Sep 10. PMID: 22975686 . A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Chauhan, et al . Cancer Cell. 2012 Sep 11,22(3):345-58. PMID: 22975377 . Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. Jung, et al . Am J Hematol. 2012 Aug 2. PMID: 22965904 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Velcade; PS-341; LDP 341; MG 341; NSC 681239
Similar products	Bortezomib, Velcade
Available
Target Information	Proteasome
Molecular Weight	384, 24
Solubility	DMSO 72 mg/mL
Bioactivity information	Bortezomib (PS-341) is a highly selective proteasome inhibitor with a ki value of 6nM.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1686-200mg-safety-datasheet.pdf